
LeMaitre Vascular, Inc.
- Jurisdiction
United States - LEI
549300FZUBUB7MHY8R17 - ISIN
US5255582018 (LMAT )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€38.21 97.6% overvalued - Financial strength (Piotroski F-Value)
-
6
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
5
/ 7
Profile
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. Read full profile
Fundamentals
- Net revenue
€200.14M - Gross margin
69.1% - EBIT
€46.72M - EBIT margin
23.3% - Net income
€40.19M - Net margin
20.1%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Stock price
Dividends
- Last dividend amount
-
$0.20 - Ex date
-
- Payment date
-
- Dividend payout ratio
-
34.5%
Analyst ratings
No analyst ratings available
Insider Transactions
Name | Title | Transaction Date | Shares | Price | Value |
---|---|---|---|---|---|
Jasinski Lawrence J | N/A |
|
|
|
|
Roberts David B | President and Director |
|
|
|
|
Roush John A | N/A |
|
|
|
|
Ross Bridget A | N/A |
|
|
|
|
LeMaitre George W | Chairman and CEO |
|
|
|
|
Earnings Calls
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Sell |
Earnings Calls
Latest earnings call: May 9, 2024 (Q1 2024)